|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 22:36
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,400 shares of common stock and 6,800 restricted stock units (“RSUs”) to five new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of $91.75 per share, which is equal to Mirum's closing trading price on March 11, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date, and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued servi...
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 19:27
|
13 Analysts Have This To Say About Mirum Pharmaceuticals (Benzinga)
|
|
|
Latest Ratings for MIRM
DateFirmActionFromTo Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022SVB LeerinkMaintainsOutperform Jan 2022Raymond JamesMaintainsStrong Buy
View More Analyst Ratings for MIRM
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.02.26 - 22:06
|
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress.
Conference call details:
Wednesday, February 25, 2026
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:
US/Toll-Free: +1 833 470 1428
International: +1 646 844 6383
Access Code: 047642
You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to p...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
